Would you recommend the following article to a politician, an athlete, a business executive, or a scientist?

AtheroGenics arthritis drug flops Stock falls on news treatment failed a mid-stage trial, company will cease developing drug. NEW YORK (Reuters) - AtheroGenics Inc.
